Inspire Medical Systems, Inc. (NYSE: INSP) has recently published the clinical outcomes data for its Inspire V system, which is designed to provide treatment for patients with obstructive sleep apnea (OSA). The data, presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical Sleep Society (ISSS) meetings, showcased the performance of the Inspire V system in both the Singapore clinical study and the limited market release in the United States.
In the Singapore clinical study, 44 patients received the Inspire V system and were followed for six months post-implant. The results showed a 20% reduction in surgical times compared to the previous generation (Inspire IV) and a 100% success rate in completing the procedures. The data also revealed that the Inspire V system demonstrated superior respiratory sensing and increased patient adherence, with an average of 5.5±1.7 hours of therapy per night at 246 days post-implant. Additionally, the median reduction in the apnea hypopnea index (AHI) decreased from 34.4 events/hour at baseline to 8.3 events/hour at month six for the 37 patients who completed the clinical visit.
In the limited market release in the United States, the company evaluated the Inspire V system at 10 leading centers with 101 patients. All procedures were successfully completed with no serious adverse events reported. At the 60-day check, all 101 patients were found to be using their therapy, with an average usage of 6.8 hours per night. Subsequent sleep study data from the first 34 patients demonstrated a median reduction in AHI from 30 to 4.5 events/hour, indicating therapeutic values.
The single-site results from two centers in the United States further supported the positive performance of the Inspire V system. Dr. Phil Huyett from the Massachusetts Eye and Ear Infirmary reported an average surgical implant time of 34.5 minutes for a standard Inspire placement, while Dr. Nic Beckmann at Colorado ENT and Allergy noted an increase in implant volume with Inspire V due to shorter procedure times, averaging 12 implants per surgery day compared to 9 cases per surgery day with Inspire IV.
As a result of these announcements, the company's shares have moved 2.04% on the market, and are now trading at a price of $80.14. For the full picture, make sure to review Inspire Medical Systems's 8-K report.
